NSCLC Clinical Trial
Official title:
A Randomized, Double-blind, Phase 2 Study of BMS-986315 and Nivolumab in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy as First-line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
The purpose of this study is to evaluate the efficacy and safety of BMS-986315 plus nivolumab in combination with platinum-based doublet chemotherapy (PDCT) versus nivolumab in combination with PDCT in the first-line treatment of Stage IV or recurrent non-small cell lung cancer (NSCLC).
| Status | Recruiting |
| Enrollment | 196 |
| Est. completion date | October 27, 2027 |
| Est. primary completion date | October 10, 2026 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - Participants must have NSCLC with Stage IV or recurrent disease following multimodal therapy for locally advanced disease. - Study treatment must be first-line therapy for Stage IV or recurrent disease. - Participants in all parts of the study must have: - measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1. (RECIST v1.1) - an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 - a life expectancy of at least 3 months at the time of first dose Exclusion Criteria: - Untreated symptomatic central nervous system metastases - Participants with epidermal growth factor receptor (EGFR)/ALK receptor tyrosine kinase (ALK)/ROS proto-oncogene 1 (ROS1)/neurotrophic tyrosine receptor kinase (NTRK)/MET proto-oncogene (MET)/B-Raf proto-oncogene (BRAF)/RET proto-oncogene (RET) mutations amenable to targeted therapies - Participants with any known medical condition that, in the investigator's opinion, would increase the risk associated with study participation or study drug administration or interfere with the interpretation of safety results Note: Other protocol-defined inclusion/exclusion criteria apply. |
| Country | Name | City | State |
|---|---|---|---|
| Argentina | Local Institution - 0020 | Buenos Aires | |
| Argentina | Local Institution - 0022 | Cordoba City | Provincia De Cordoba |
| Argentina | Local Institution - 0001 | Rio Cuarto | Cordoba |
| Argentina | Local Institution - 0002 | Viedma | Rio Negro |
| Australia | Local Institution - 0032 | Joondalup | Western Australia |
| Australia | Local Institution - 0013 | St Leonards | New South Wales |
| Australia | Local Institution - 0021 | Tweed Heads | New South Wales |
| Chile | Local Institution - 0043 | Vina Del Mar | Valparaiso |
| France | Local Institution - 0054 | Paris Cedex 05 | Ile De France |
| Italy | Local Institution - 0009 | Parma | |
| Italy | Local Institution - 0006 | Rome | |
| Poland | Local Institution - 0015 | Gdansk | Pomorskie |
| Poland | Local Institution - 0056 | Krakow | Malopolskie |
| Romania | Local Institution - 0060 | Cluj-napoca | |
| Romania | Local Institution - 0062 | Cluj-Napoca | |
| Romania | Local Institution - 0066 | Cluj-Napoca | Cluj |
| Romania | Local Institution - 0061 | Craiova | |
| Romania | Local Institution - 0065 | Floresti | |
| Spain | Local Institution - 0027 | Madrid | |
| United States | Local Institution - 0041 | Baltimore | Maryland |
| United States | Saint Alphonsus Regional Medical Center | Boise | Idaho |
| United States | The Medical University of South Carolina | Charleston | South Carolina |
| United States | Clermont Oncology Center | Clermont | Florida |
| United States | Los Angeles Cancer Research | Glendale | California |
| United States | Millennium Research & Clinical Development | Houston | Texas |
| United States | Mid Florida Hematology and Oncology Center | Orange City | Florida |
| United States | MAYO | Rochester | Minnesota |
| United States | Swedish Cancer Institute | Seattle | Washington |
| Lead Sponsor | Collaborator |
|---|---|
| Bristol-Myers Squibb |
United States, Argentina, Australia, Chile, France, Italy, Poland, Romania, Spain,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Part 1: Number of Participants with Adverse Events (AEs) | Up to 100 days after discontinuation of study treatment | ||
| Primary | Part 1: Number of Participants with Treatment-related AEs (TRAEs) | Up to 100 days after discontinuation of study treatment | ||
| Primary | Part 1: Number of Participants with Serious AEs (SAEs) | Up to 100 days after discontinuation of study treatment | ||
| Primary | Part 1: Number of Participants with AEs Meeting Protocol-defined Dose Limiting Toxicity DLT Criteria | Up to 100 days after discontinuation of study treatment | ||
| Primary | Part 1: Number of Participants with AEs Leading to Discontinuation | Up to 100 days after discontinuation of study treatment | ||
| Primary | Part 1: Number of Participants with AEs Leading to Death | Up to 100 days after discontinuation of study treatment | ||
| Primary | Part 2: Objective Response Rate (ORR) | Up to 5 years | ||
| Secondary | Part 2: Progression Free Survival (PFS) | Up to 5 years | ||
| Secondary | Part 2: Number of Participants with AEs | Up to 100 days after discontinuation of study treatment | ||
| Secondary | Part 2: Number of Participants with TRAEs | Up to 100 days after discontinuation of study treatment | ||
| Secondary | Part 2: Number of Participants with SAEs | Up to 100 days after discontinuation of study treatment | ||
| Secondary | Part 2: Number of Participants with AEs Meeting Protocol-defined Dose Limiting Toxicity DLT Criteria | Up to 100 days after discontinuation of study treatment | ||
| Secondary | Part 2: Duration of Response (DOR) | Up to 5 years | ||
| Secondary | Part 2: Time to Response (TTR) | Up to 5 years | ||
| Secondary | Part 2: Disease Control Rate (DCR) | Up to 5 years | ||
| Secondary | Part 2: Maximum Observed Serum Concentration (Cmax) | Predose and postdose up to 2 years | ||
| Secondary | Part 2: Time of Cmax (Tmax) | Predose and postdose up to 2 years | ||
| Secondary | Part 2: Area Under the Serum Concentration-time Curve from Time Zero to Time of Last Quantifiable Concentration (AUC[0-T]) | Predose and postdose up to 2 years | ||
| Secondary | Part 2: Number of Participants with Anti-drug Antibodies to BMS-986315 | Up to 5 years |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05821933 -
RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03269162 -
Postoperative NSCLC Treated With Integrated Medicine Base on Circulating Tumor Cell Detection
|
Phase 3 | |
| Recruiting |
NCT05002270 -
JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06315686 -
The Dynamic Monitoring of Cerebrospinal Fluid ctDNA
|
Phase 2 | |
| Active, not recruiting |
NCT05059522 -
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
|
Phase 3 | |
| Recruiting |
NCT05466149 -
Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion
|
Phase 2 | |
| Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
| Completed |
NCT03609918 -
Comprehensive Analysis of Gene Mutation Profile in Chinese NSCLC Patients by Next-generation Sequencing
|
||
| Recruiting |
NCT06043817 -
First-In-Human Study of STX-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
|
Phase 1/Phase 2 | |
| Completed |
NCT03652077 -
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
|
Phase 1 | |
| Recruiting |
NCT05078931 -
A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients
|
Phase 2 | |
| Not yet recruiting |
NCT05547737 -
Multicenter, Prospective, Real World Study of Camrelizumab in Cross-line Treatment of Non-small Cell Lung Cancer
|
||
| Not yet recruiting |
NCT05909137 -
Omitting Clinical Target Volume in Radical Treatment of Unresectable Stage III Non-small Cell Lung Cancer
|
||
| Withdrawn |
NCT05959473 -
EGFR_IUO 3.20 Clinical Study Protocol
|
N/A | |
| Not yet recruiting |
NCT05005468 -
A Phase II Trial of Camrelizumab Combined With Famitinib for Adjuvant Treatment of Stage II-IIIA NSCLC.
|
Phase 2 | |
| Recruiting |
NCT01690390 -
Dose Escalation of Icotinib in Advanced Non-small Cell Lung Carcinoma (NSCLC) Patients Evaluated as Stable Disease
|
Phase 2 | |
| Completed |
NCT01852578 -
Cabazitaxel in Relapsed and Metastatic NSCLC
|
Phase 2 | |
| Active, not recruiting |
NCT01460472 -
Immunotherapy With Racotumomab in Advanced Lung Cancer
|
Phase 3 | |
| Completed |
NCT00866970 -
Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and Cachexia
|
Phase 2 | |
| Completed |
NCT00702975 -
Study of Combination Therapy of Carboplatin -Gemcitabine Plus Bevacizumab Beyond Progression in Patients With Locally Advanced and/or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Received Prior Systemic Therapy
|
Phase 2 |